Creating the Next Wave of Multifunctional Antibodies

Wireframe-like 3D rendering of an orange T cell attacking a larger, light blue tumor cell, set on a navy blue background.

We Are Innovating Along the Third Arc of Antibody Therapeutics

Our company is advancing the next major wave of antibody technology, which we call the "Third Arc." During the "first arc" of antibody therapeutics, drugs were typically designed to engage a single target, often a cytokine or a cell surface protein. The "second arc" advanced the capabilities of antibodies with novel Fc engineering or payloads. Now, the "Third Arc" of biologics leverages the transformational capabilities of multifunctional antibodies that engage multiple targets and multiple cell types.

Third Arc Bio's approach unlocks the powerful biology of immune synapses to address large unmet need in complex disease areas like solid tumors and immunology and inflammation (I&I).

Illustration of a light blue target protein featuring a green "Epitope 1" region at the top of the protein and an orange "Epitope 2" region on the lower right side against a navy blue background.

Third Arc Bio engineers fully optimized biologics by starting with binders that engage the ideal epitopes to deliver superior function.

Explore Our Science Discover Our Pipeline

Illustration of Third Arc Bio's multispecific antibodies in light green, light blue, and white against a navy blue background.

A World-Class Team With a Proven Track Record

Our C-suite collectively has brought 19 novel drugs to market, including multiple therapies that have redefined the standard of care in oncology and I&I.